iBio, Inc., an innovator in precision antibody immunotherapies, announced the expansion of its cardiometabolic and obesity treatment program by in-licensing a long-acting anti-myostatin antibody, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results